Park Square has placed Loïc Vincent, Ph.D. as Chief Scientific Officer at Korro Bio.
| less than a minute read
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company’s Chief Scientific Officer.

/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-23-14-44-49-507-6ab3e5e1470f335536fcf89c.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-22-15-19-50-498-6ab29c96af556e9074387689.jpg)
/Passle/58a5cb8db00e8110e83aa395/MediaLibrary/Images/2026-09-15-18-23-35-620-6aa98d270810fd5205abd644.png)